SUPERCHARGED PROTEINS FOR CELL PENETRATION
    1.
    发明公开
    SUPERCHARGED PROTEINS FOR CELL PENETRATION 审中-公开
    SUPRA电荷的蛋白质用于细胞渗透

    公开(公告)号:EP2424877A2

    公开(公告)日:2012-03-07

    申请号:EP10772365.2

    申请日:2010-04-28

    IPC分类号: C07K14/00

    摘要: Compositions, preparations, systems, and related methods for delivering a supercharged protein, or a complex of a supercharged protein and an agent (e.g., nucleic acids, peptides, proteins, small molecules) to cells are provided. Such systems and methods include the use of supercharged proteins. For example, superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. In some embodiments, such systems and methods involve altering the primary sequence of a protein in order to "supercharge" the protein (e.g., to generate a superpositively-charged protein). In some embodiments, complexes comprising supercharged proteins and one or more agents to be delivered are useful as therapeutic agents. In some embodiments, complexes and/or pharmaceutical compositions thereof are administered to a subject in need thereof. The inventive complexes or pharmaceutical compositions thereof may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc.

    SUPERCHARGED PROTEINS FOR CELL PENETRATION
    2.
    发明公开
    SUPERCHARGED PROTEINS FOR CELL PENETRATION 审中-公开
    SUPER电荷的蛋白质用于细胞渗透

    公开(公告)号:EP2297182A2

    公开(公告)日:2011-03-23

    申请号:EP09739610.5

    申请日:2009-04-28

    IPC分类号: C07K14/00 A61K47/42

    CPC分类号: A61K38/17

    摘要: Compositions, systems and related methods for delivering a supercharged protein or a complex of a supercharged protein and therapeutic agent (e g, nucleic acid, peptide, small molecule) to cells are disclosed. Superpositively charged proteins may be associated with nucleic acids (which typically have a net negative charge) via electrostatic interactions. The systems and methods may involve altering the primary sequence of a protein in order to "supercharge" the protein (e g, to generate a superpositively-charged protein). The compositions may be used to treat proliferative diseases, infectious diseases, cardiovascular diseases, inborn errors in metabolism, genetic diseases, etc.